Is it true that I receive a higher dose of Taxol® (paclitaxel) if I receive Abraxane® (nanoparticle albumin-bound [NAB] paclitaxel)?
It is true that a higher dose of NAB paclitaxel was compared with the standard dose of paclitaxel in a clinical trial that showed the superiority of NAB paclitaxel in terms of likelihood of shrinking the tumors and time to disease progression. This higher dose is possible because NAB paclitaxel is not dissolved in Cremophor. Cremophor produces side effects, such as allergic reaction, potential for nerve damage, and potential for entrapping the drug thus impairing its delivery to the tumor. NAB paclitaxel, on the other hand, binds paclitaxel to albumin, a natural protein, making it soluble. This enables a much shorter delivery time compared with traditional paclitaxel (one-half hour instead of 3 hours) and avoids the multiple medications given with paclitaxel to prevent an allergic reaction to Cremophor. This also enables a higher dose of paclitaxel to be delivered in the NAB paclitaxel formulation, which perhaps results in better efficacy of the drug.
Related Questions
- Can Abraxane® (nanoparticle albumin-bound [NAB] paclitaxel) be given instead of Taxol® (paclitaxel) in the postoperative treatment of cancer?
- Is it true that I receive a higher dose of Taxol® (paclitaxel) if I receive Abraxane® (nanoparticle albumin-bound [NAB] paclitaxel)?
- Is Abraxane® (nanoparticle albumin-bound [NAB] paclitaxel) as good as Taxotere® (docetaxel)?
